Compare Marvell Technology Inc (MRVL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Sanofi SA — how do they compare? Marvell Technology Inc trades at $275.28 (market cap $246.84B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Marvell Technology Inc is far larger — about 2.6× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Sanofi SA for 94 Days on average.
| MRVL | SNY | |
|---|---|---|
Market Cap | $246.84B | $95.18B |
Volume | 29,003,830 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $316.43 | $52.34 |
52-Week Low | $73.73 | $39.51 |
Typical Hold Time | 42 Days | 94 Days |
Enterprise Value | $248.19B | $114.48B |
Dividend Yield | 0.09% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $274.66, down 3.52% on the day, but maintains strong analyst support with 84% buy ratings and a $327.86 consensus price target. The stock shows bullish technical signals with support at $267 and resistance at $282, while recent earnings beats and projected revenue growth to $9.5B in 2026 highlight fundamental momentum. Management's raised 2028 revenue guidance to $18B and major hyperscaler deals underscore the company's positioning in AI infrastructure.
Outlook remains positive driven by AI chip demand and custom silicon growth, though high valuations (P/E 90.95) and margin pressures present risks. The stock offers significant upside to analyst targets but requires monitoring of execution against aggressive growth forecasts and competitive dynamics in the semiconductor space.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
